Bexarotene therapy ameliorates behavioral deficits and induces functional and molecular changes in very-old Triple Transgenic Mice model of Alzheimer´s disease

PLoS One. 2019 Oct 9;14(10):e0223578. doi: 10.1371/journal.pone.0223578. eCollection 2019.

Abstract

Introduction: Bexarotene, a retinoid X receptor agonist, improves cognition in murine models of Alzheimer's disease (AD). This study evaluated the effects of bexarotene on pathological and electrophysiological changes in very old triple transgenic AD mice (3xTg-AD mice).

Methods: 24-month-old 3xTg-AD mice were treated with bexarotene (100 mg/kg/day for 30 days). The Morris water maze was used to evaluate spatial memory; immunofluorescence and confocal microscopy were used to evaluate pathological changes; and in vivo electrophysiological recordings were used to evaluate basal transmission and plasticity in the commissural CA3-CA1 pathway.

Results: In addition to cognitive improvement, bexarotene-treated 3xTg-AD mice were found to have 1) reductions of astrogliosis and reactive microglia both in cortex and hippocampus; 2) increased ApoE expression restricted to CA1; 3) increased number of cells co-labeled with ApoE and NeuN; 4) recovery of NeuN expression, suggesting neuronal protection; and, 5) recovery of basal synaptic transmission and synaptic plasticity.

Discussion: These results indicate that bexarotene-induced improvement in cognition is due to multiple changes that contribute to recovery of synaptic plasticity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alzheimer Disease / drug therapy*
  • Alzheimer Disease / genetics
  • Animals
  • Apolipoproteins E / metabolism
  • Bexarotene / pharmacology
  • Bexarotene / therapeutic use*
  • DNA-Binding Proteins / metabolism
  • Female
  • Gliosis
  • Hippocampus / drug effects*
  • Hippocampus / growth & development
  • Hippocampus / metabolism
  • Hippocampus / physiopathology
  • Male
  • Maze Learning
  • Mice
  • Nerve Tissue Proteins / metabolism
  • Neuroglia / metabolism
  • Neuronal Plasticity
  • Neuroprotective Agents / pharmacology
  • Neuroprotective Agents / therapeutic use*
  • Synaptic Transmission

Substances

  • Apolipoproteins E
  • DNA-Binding Proteins
  • Nerve Tissue Proteins
  • NeuN protein, mouse
  • Neuroprotective Agents
  • Bexarotene

Grants and funding

This research was funded by Colombian Science, Technology and Innovation Department (Colciencias) grants (621-2014-110165843270), (727-2018-110180763833), (761-2013-110161538259), and (RC110189666226); and by DIEB-Universidad Nacional de Colombia. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.